• Markets
    • icon
  • Companies
ALA · ASX

Arovella Therapeutics Limited (ASX:ALA)

AU$0.089

 -0.003 (-3.261%)
ASX:Live
28/11/2023 03:55:22 PM
HALO Price Momentum HALO Ords HALO Momentum HALO Earnings Momentum GROWTH AUS +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ALA Overview

ALA Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About ALA

Website

Arovella Therapeutics Limited

Telephone

61.3.9824.5254

Address

Level 3, Suite 1 62 Lygon Street Carlton South, Victoria (VIC) 3053

Description

Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. Its technologies include iNKT cell therapy, CAR19-iNKT + CF33-CD19, CLDN18.2-iNKT, and DKK1-CAR-iNKT. The company was founded on December 21, 1999 and is headquartered in Carlton South, Australia.

ALA Price Chart

Key Stats

Market Cap

AU$78.11M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.11

Trade Value (12mth)

AU$40,158.00

1 week

7.23%

1 month

-1.11%

YTD

270.83%

1 year

270.83%

All time high

14.7798

Key Fundamentals

EPS 3 yr Growth

-76.500%

EBITDA Margin

%

Operating Cashflow

-$6m

Free Cash Flow Return

-75.20%

ROIC

-103.40%

Interest Coverage

-36.20

Quick Ratio

4.40

Other Data

Shares on Issue (Fully Dilluted)

671m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ALA Announcements

Latest Announcements

Date Announcements

31 October 22

Quarterly Appendix 4C and Activities Report

×

Quarterly Appendix 4C and Activities Report

31 January 23

Quarterly Appendix 4C and Activities Report

×

Quarterly Appendix 4C and Activities Report

31 January 22

Quarterly Appendix 4C and Activities Report

×

Quarterly Appendix 4C and Activities Report

31 January 22

Becoming a substantial holder

×

Becoming a substantial holder

31 August 23

Response to ASX Price Query

×

Response to ASX Price Query

31 August 23

Appendix 4E and Annual Report

×

Appendix 4E and Annual Report

31 August 23

Corporate Governance Statement

×

Corporate Governance Statement

31 August 23

Appendix 4G

×

Appendix 4G

31 August 23

2023 ESG Report

×

2023 ESG Report

31 August 22

Preliminary Final Report

×

Preliminary Final Report

30 October 23

AusBiotech Invest Presentation

×

AusBiotech Invest Presentation

30 November 22

Proposed issue of securities - ALA

×

Proposed issue of securities - ALA

30 January 23

Change in substantial holding

×

Change in substantial holding

29 September 22

Annual Report to shareholders

×

Annual Report to shareholders

29 September 22

Corporate Governance Statement

×

Corporate Governance Statement

29 September 22

Appendix 4G

×

Appendix 4G

29 November 22

R&D Tax Incentive refund received

×

R&D Tax Incentive refund received

29 November 21

R&D Tax Incentive refund received

×

R&D Tax Incentive refund received

29 June 23

Share Purchase Plan (SPP) Closing Date Extended

×

Share Purchase Plan (SPP) Closing Date Extended

29 June 23

Update - Proposed issue of securities - ALA

×

Update - Proposed issue of securities - ALA

29 June 22

Notification regarding unquoted securities - ALA

×

Notification regarding unquoted securities - ALA

29 July 22

Quarterly Appendix 4C and Activities Report

×

Quarterly Appendix 4C and Activities Report

28 November 23

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

28 November 23

Notice Under Section 708A

×

Notice Under Section 708A

28 March 23

Arovella iNKT Cell Platform Explanatory Webinar

×

Arovella iNKT Cell Platform Explanatory Webinar

28 June 22

Sumatriptan Update

×

Sumatriptan Update

28 February 22

Appendix 4D and Half Year Report

×

Appendix 4D and Half Year Report

28 February 22

Update - Proposed issue of securities - ALA

×

Update - Proposed issue of securities - ALA

ALA Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.06 -0.02 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.06 -0.02 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 11.5 74.3 -3.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.01 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.02 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -297.4 68.2 -44.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -57.5 -19.7 -49.9 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.02 0.02 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock -0.00 0.01 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -103.1 1,930.6 -36.6 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 168 331 550 Lock Lock Lock
Basic m Lock Lock Lock Lock 168 331 550 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Income Statement
Sales $m Lock Lock Lock Lock 1 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -56.3 -51.7 14.9 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 3 3 5 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -153.1 -19.2 -23.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -303.1 -747.6 -800.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 403 848 900 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -4 -4 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -120.5 4.2 -74.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -790.6 -1,568.2 -2,381.6 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -5 -5 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -100.9 2.0 -62.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -898.0 -1,821.6 -2,568.0 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -5 -6 -9 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -1 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -10 -5 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -27.5 49.2 -70.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,865.2 -1,961.3 -2,914.2 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -3 -4 -6 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -1 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 10 6 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -3 -4 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -7.7 -22.7 -69.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -5.7 -14.4 -21.3 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 1 7 6 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 7 11 9 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -1 -7 -6 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 3 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 4 9 8 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 4 9 8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -70.4 117.0 -14.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -148.1 -47.2 -93.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -240.3 -56.2 -113.2 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -113.3 -70.6 -90.3 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -102.2 -76.9 -103.4 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -69.7 -54.0 -75.2 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Leverage
Interest Cover X Lock Lock Lock Lock -197.9 -121.2 -36.2 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.2 1.6 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -21.6 -73.9 -77.8 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 1.0 4.3 4.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 1.0 4.3 4.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 48.0 91.5 92.2 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -142.6 -209.1 -415.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.5 0.3 1.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 98.5 200.1 N/A Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 43.8 0.0 0.1 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 137.4 88.4 254.2 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.1 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.1 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -917.4 -2,207.1 -2,914.2 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -72.9 -53.1 -93.6 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -148.1 -47.2 -93.6 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.6 1.2 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -240.3 -56.2 -113.2 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -240.3 -56.2 -113.2 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 3.7 1.8 N/A Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 678.0 1,080.6 352.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 681.7 1,082.4 352.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 124.4 81.1 67.1 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 557.3 1,001.3 284.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ALA Shortsell

Frequently Asked Questions

The current share price of Arovella Therapeutics Limited (ALA:ASX) is AU$0.089.
The 52-week high share price for Arovella Therapeutics Limited (ALA:ASX) is AU$0.11.
The 52-week low share price for Arovella Therapeutics Limited (ALA:ASX)? is AU$0.02.
Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.
Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.
Arovella Therapeutics Limited (ALA:ASX) has a franking level of 0%.
Arovella Therapeutics Limited (ALA:ASX) is classified in the Healthcare.
The current P/E ratio for Arovella Therapeutics Limited (ALA:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.